The U.S. Food and Drug Administration announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications.  These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia.  Avandia will now only be sold in the U.S. if a doctor justifies their decision to prescribe it for their patient.

In a coordinated effort, Avandia will no longer be available for sale in Europe.  Click here to read an informative article in the Washington Post about Avandia sales.

At The Brandi Law Firm, our Avandia Attorneys are representing people who have taken this drug and suffered the reported side effects.  Avandia has had a history of problems that has resulted in these restrictions.